demonstrated by immunoprecipitation of 35S-labeled proteins. The results suggested that the addition of the nonpolar residue to a polypeptide precursor is important for the production of tremerogen v4-10, especially in the intracellular transport and processing of the precursor molecules.
Sexual conjugation of haploid cells of two compatible mating types (AB and ab) of the heterobasidiomycetous yeast Tremella mesenterica is mediated by mating-type specific diffusible pheromones.1} The pheromones elicit metabolic and morphological changes in the target cell having the mating type opposite to the pheromone producer cell.1"3* Tremerogen^4-10 (TA-10),4) the mating pheromone produced by the AB cells, has been purified to homogeneity and its chemical structure is a lipopeptide with an S-polyisoprenyl cysteine residue at the carboxy terminus of the peptide (Fig. 1) . The nonpolar residue of the pheromone is indispensable for its biological activity.5) The residue may also be important for the production of the mating pheromone, especially in the process of secretion across the membrane.The assessment of the significance of the nonpolar residue for the secretory process of TA-10 would be facilitated by the use of inhibitors of the synthesis of polyisoprene. Compactin (ML 236-B) is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase in mammalian cells6) and has been widely used to study biochemical and physiological effect of the inhibition of the synthesis of mevalonate and its metabolites. In order to test the possibility of exploiting compactin as a tool for the study of TA-10 synthesis, weinvestigated the biochemical effect of the drug on this organisms and the effect of the drug on the production of TA-10. In this paper we show that the drug specifically inhibits the synthesis of mevalonate and that TA-10 production is blocked with accumulation of a membrane-bound very high molecular weight precursor.
MATERIALS AND METHODS
Microorganisms and growth conditions. Haploid strains of Tremella mesenterica UBC6106-1 (mating type AB) H-Glu-His-Asp-Pro-Ser-Ala-Pro-Gly-Asn-Gly-Tyr-Cys-OCH3 Fig. 1 KOH-ethanol (w/v) and heated in a water bath at 75°C for 90min to saponify cellular lipids. The resulting suspension was centrifuged at 6,000 x g for lOmin to remove cell debris. Nonsaponifiable lipids in the supernatant solution were extracted three times with 1 ml portions of petroleum ether. The aqueous phase was then acidified by the addition of 6n HC1, followed by extraction with petroleum ether as above to obtain fatty acids. The pooled organic phase was evaporated to dryness, dissolved in a small volume of chloroform-methanol (2 : 1, v/v), spotted onto filter paper (2-cm diameter) and the radioactivity was determined in a liquid scintillation counter.
RESULTS AND DISCUSSION
First, we tested the effect of various concentrations of compactin on the growth and extracellular production of TA-10 by ABcells (Fig.. 2) . We previously demonstrated that TA-10 is initially synthesized as high molecular weight precursors when the cell growth starts to decline toward the end of logarithmic phase, followed by secretion of the mating pheromone into the medium for about 30h, and the pheromone production ceases thereafter.10)
Thus, compactin was added to an exponentially growing cell culture at a cell density of 1 x 107cells/ml, a time before the precursor accumulation, and cultivated for 72 h until the pheromone production was virtually completed in control culture. In the absence of compactin, the cell number increased about 18-fold during the cultivation period. The cell growth was inhibited 50% by the drug at a concentration of lOO^g/ml (Fig. 2) . The concentrations of the drug required for the growth inhibition of this organisms was much higher Cells (mating type AB) growing exponentially in MMwere diluted with fresh MMto adjudt the cell concentration to 1 x 107 cells/ml. To the 5-ml cell suspensions were added various concentrations of compactin, and the cells were cultivated in test tubes (1.8cm by 18cm) at 28°C for 72hr with shaking. Cell number was counted under a microscope using a hemocytometer. Pheromoneactivity was determined as described in Materials and Methods.
Compactin had no influence on the biological assay of the pheromoneat the drug concentrations used. Cell number and mating pheromoneactivity were determined as described in Materials and Methods. Compactin and mevalonate had no influence on the biological assay of the pheromone at the concentrations used.
than those reported for mammalian cells,6) possibly due to poor permeability of the drug through the cell surface. The pheromone production was moresensitive to compactin than cell growth: 50% inhibition of the pheromone production was attained at about 12 /ig/ml of compactin, in contrast to 100/ig/ml for 50% Fig. 4 . Reversibility of the Inhibitory Effect of Compactin on the Growth and TA-10 Production. The cells were grown as described in Fig. 2 . At the times indicated by the arrows, compactin was added to a final concentration of 100 /ig/ml. After 72 hr of incubation, the cell cultures were centrifuged at 3,000 rpm for lO min and the supernatant fraction was isolated and saved for pheromoneassay (medium I). The cells were washed once with MM,suspended in the same volume (5ml) of fresh MM and cultivated further for 48 hr. Cell-free culture medium was isolated as described above for pheromone assay (medium II).
inhibition of cell growth. Both cell growth and pheromone production affected by lOO /ig/ml ofcompactin were restored to normal levels by mevalonate added to the medium (Table I by compactin. The concentration of the drug for 50% inhibition of sterol synthesis from acetate was close to that of TA-10 production (Fig. 2) . In contrast, sterol synthesis from [14C]mevalonate was not inhibited by the drug at the concentrations tested (0~100/*g/ml) (Fig. 3A) . Thus, it was concluded that the synthesis of mevalonate from acetate was specifically inhibited by compactin. Protein synthesis was not inhibited by compactin (Fig. 3C) . These properties are useful in using the drug to investigate TA-10 production by specifically inhibiting the synthesis of the polyisoprene moiety of the pheromone.
Reversibility of the inhibition by compactin of cell growth and TA-10 production was examined. As seen in Fig. 4 , when the cells cultivated in the presence of 100/ig/ml of compactin were transferred to fresh medium free of the drug, the cells resumed exponential growth after a short lag period. A significant amount of mating pheromone was produced during cultivation for 48 h following the shift to new mediumfree of the drug (Fig. 4) . The ready reversibility of the inhibition by compactin in the yeast cells is in accord with the competitive inhibitory mechanism of compactin for HMG CoAreductase in mammalian cells.6) We previously showed by radioimmunoassay with antibody directed against the peptide moiety of TA-10 that biologically inactive TA-10 analogue(s) accumulate in the cell during the inhibition of TA-10 production by compactin.10) The results indicated that TA-10precursors accumulate as the result of inhibition of mevalonate synthesis. Thus, molecular species of TA-10 precursors which accumulate in the cell during inhibition of TA-10 production were analyzed and compared with those present in untreated cells. TA-10 precursors in the cell extracts of 35S-labeled cell were isolated by immunoprecipitation and analyzed by SDS-urea polyacrylamide gel electrophoresis.
The fluorographic pattern in Fig. 5 shows the presence of precrusors of various sizes in the control cells. Polypeptide species of MW28,000, 7,800, and 2,800 were specifically precipitated by the immuneserum.
In contrast, only the MW28,000 species was immunoprecipitated in compactin-treated cells. The results suggested that TA-10 (MW 1,480) was produced as a result of processing of very high molecular weight peptides and that compactin blocked secretion of TA-10 by inhibition of the processing, with intracellular accumulation of the MW28,000 precursor.
Thus, the addition of polyisoprene residue(s) to the precursor peptide appeared to be necessary for further processing of the high molecular weight precursor molecule. Absence of the nonpolar residue in the MW28,000 molecule still needs to be demonstrated. In the presence of tunicamycin, an inhibitor of protein glycosylation,13) however, a polypeptide of MW12,000 accumulated.10) The difference of molecular species accumulated by the two inhibitors indicated that inhibition of TA-10 synthesis by compactin is not due to inhibition of protein glycosylation through inhibition of the synthesis of carrier lipid, but that the drug inhibits farnesylation of the precursor. The MW28,000 peptide, a putative unfarnesylated precursor, was present exclusively in the membrane fraction and was absent in the cytosol fraction (unpublished data), indicating that the site of addition of the nonpolar residue is on the membrane. Detailed studies of the biosynthesis and secretion of TA-10 with various drugs including compactin will be reported elsewhere.10)
